{"slug":"incyte","name":"인사이트","name_en":"Incyte","ticker":"INCY","updated_at":"2026-07-11T10:20:22.47+00:00","canonical":"https://valuechain.wiki/incyte","kicker":"헬스케어 · S&P 500","kicker_en":"Health Care · S&P 500","lead":"항암제와 자가면역질환 치료제를 개발하고 판매하는 미국의 바이오제약 기업이다. S&P 500 구성종목. 섹터: 헬스케어(Biotechnology). 밸류체인 관계·수치 데이터는 조사 전인 기본 노드로, AI 질문 수요가 관측되면 상세 노드로 승격된다.","lead_en":"A U.S. biopharmaceutical company that develops and markets oncology and autoimmune disease treatments. S&P 500 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.","segments":{"parts":[{"name":"자카피(룩솔리티닙)"},{"name":"옵젤루라"},{"name":"기타 제품·로열티"}],"total":"약 $4.2B (FY2024)"},"segments_en":{"parts":[{"name":"Jakafi (ruxolitinib)"},{"name":"Opzelura"},{"name":"Other products & royalties"}],"total":"~$4.2B (FY2024)"},"returns_yearly":{"2021":-15.6,"2022":9.4,"2023":-21.8,"2024":10,"2025":43,"2026":18.2},"return_asof":"2026-07-10","value_chain":{"leading":[],"benefiting":[],"analysis":null,"analysis_en":null,"analysis_asof":null},"edges":[]}